Asenapine (USAN, rINNM and BANM; trade names Saphris (AU, US, RU), Sycrest (EU, UK)) is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder by Schering-Plough after its November 19, 2007 merger with Organon International. Development of the drug, through Phase III trials, began while Organon was still a part of Akzo Nobel. Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 patients have participated in clinical trials of asenapine, and the FDA approved the manufacturer's NDA in August 2009.
It was chemically derived via altering the chemical structure of the tetracyclic (atypical) antidepressant, mianserin.

Chemical Name	Asenapine
Synonyms	L-Ascorbic Acid 6-Palmitate;scorbicpalmitate;Vitamin C Palmitate;<36Cl>-trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz<2,3:6,7>oxepino<4,5-c>pyrrole;6-palmitoylascorbic acid;trans-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz<2,3:6,7>oxepino<4,5-c>pyrrolidine;Collapse
CAS No.	65576-45-6
Molecular Formula	C17H16ClNO
Molecular Weight	285.76800
PSA	12.47000
LogP	4.19640

EINECS number	265-829-4

Appearance & Physical State	COA
Density	1.231
Boiling Point	357.9ºC at 760 mmHg
Flash Point	170.2ºC
Refractive Index	1.609

HS Code	2934999090